Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 3 of 5 (60%) have an AI response strategy ready • 3 patents granted in the last 365 days
Csl Innovation Pty Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners across 3 art units, combining examiner diversity with some art-unit overlap.
BENAVIDES, JENNIFER ANN is the busiest examiner, with 1 pending matter. The art-unit overlap may support targeted consistency checks, while examiner-specific issues still require separate attention.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §102 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17299590 | METHOD OF TREATING NEUTROPHILIC CONDITIONS | JUEDES, AMY E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037219 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | LU, CHENG | 35d |
| 18037342 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | BENAVIDES, JENNIFER ANN | 82d |
| 18037397 | PROTEIN FORMULATIONS AND USES THEREOF | OUSPENSKI, ILIA I | — |
| 17781995 | USE OF AN ANTI-FACTOR XII ANTIBODY FOR THE TREATMENT OR PREVENTION OF HEREDITARY ANGIOEDEMA | BERHANE, SELAM | — |
| 17299590 | METHOD OF TREATING NEUTROPHILIC CONDITIONS | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1675 | 2 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037397 | PROTEIN FORMULATIONS AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | §102 | Final Rejection | — | AI Ready | May 17, 2023 |
| 18037342 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | 82d | AI Ready | May 17, 2023 |
| 18037219 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | LU, CHENG | 1642 | §103DP | Final Rejection | 35d | AI Ready | May 16, 2023 |
| 17781995 | USE OF AN ANTI-FACTOR XII ANTIBODY FOR THE TREATMENT OR PREVENTION OF HEREDITARY ANGIOEDEMA | BERHANE, SELAM | 1675 | §102 | Final Rejection | — | Pending | Jun 02, 2022 |
| 17299590 | METHOD OF TREATING NEUTROPHILIC CONDITIONS | JUEDES, AMY E | 1644 | §103§112 | Final Rejection | — | Pending | Jun 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCsl Innovation Pty Ltd. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Ilia I Ouspenski has the most, with 1 of Csl Innovation Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
